AP-163

N/A

Report date: 2026/03/19 17:03:24

Base Information

Drug NameAP-163

Drug Alias NameAP-163

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsAnti-BCMA +[4]

TargetsB-cell maturation proteinT cell surface glycoprotein CD3

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesLunan Pharmaceutical Group Co

China Registration ClassN/A

Develop Information

Active CompaniesLunan Pharmaceutical Group Co

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A